BioTuesdays

Category - Feature

Feature

Alcobra’s ADHD program moving to pediatrics

By Len Zehr With the recent start of the first of two pivotal trials in adults with attention deficit hyperactivity disorder (ADHD), Alcobra Pharma (NASDAQ:ADHD) is now turning its attention to advancing its pediatric...

January 14, 2014
Feature

In conversation with Bing Yao

By Len Zehr As an SVP of AstraZeneca’s (NYSE:AZN) MedImmune unit, Bing Yao heads the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit at MedImmune, leading a team dedicated to the strategy...

January 7, 2014
Feature

Anavex readies trial of AZ combo drug

By Len Zehr Anavex Life Sciences (OTCQB:AVXL) plans to begin a Phase 1b/2a clinical trial in the first quarter of 2014 of a novel combination drug candidate for the treatment of Alzheimer’s disease (AD). “In preclinical...

December 17, 2013
Feature

Boston Therapeutics planning pivotal trial

By Len Zehr Boston Therapeutics (OTCQB:BTHE) hopes to begin a pivotal Phase 3 trial, by the second or third quarter of 2014, of a chewable tablet that is designed to be taken before meals to reduce post-meal elevation...

December 10, 2013
Feature

Aurinia readies Phase 2b trial in lupus nephritis

By Len Zehr Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for...

November 19, 2013
Feature

DARA’s sales team goes on a Mission

By Len Zehr A new sales and marketing venture with a unit of Mission Pharmacal gives DARA BioSciences (NASDAQ:DARA) a formidable leg up in the oncology supportive care sector to address ongoing areas of medical need. A...

November 12, 2013
Feature

In conversation with Paul Lem

By Len Zehr As CEO and co-founder of closely-held Spartan Bioscience, Dr. Paul Lem has a diverse background in clinical medicine, molecular biology research and as a biotech entrepreneur. Prior to co-founding Spartan in...

November 5, 2013
Feature

NeoStem completing enrollment in heart trial

By Len Zehr NeoStem (NASDAQ:NBS) is on track to complete enrollment later this year in a Phase 2 clinical trial of a bone marrow-derived cell therapy to treat patients for acute myocardial infarction, with a data...

October 29, 2013
Feature

Heat Biologics readies proof-of-concept studies

By Len Zehr After a successful $27-million IPO in the summer, Heat Biologics (NASDAQ:HTBX) plans to begin two proof-of-concept trials later this year of its platform to transform living cancer cells into pumps that...

October 22, 2013
Feature

CytRx awaiting soft tissue sarcoma data in December

By Len Zehr What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when...

October 15, 2013